Delivery Order SPE2DB24D9144-SPE2DB25FCNAA
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its location in Park Ridge, IL. This delivery order was issued without a set-aside designation and carries an ultimate completion date of September 16, 2025. The award represents a...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes valued at $12,379.20. This firm fixed-price delivery order, issued on September 9, 2025, is expected to be completed by September 30, 2025, and operates under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at approximately $500 million through...
- The U.S. Defense Logistics Agency Medical Supply Chain issued a firm fixed-price delivery order valued at $1,712.22 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml. The award was made on July 30, 2025, with an ultimate completion date of August 13, 2025, and will be performed at the vendor's location in Park Ridge, Illinois. This delivery order carries no set-aside designation and represents a discrete purchase under DMS Pharmaceutical Group's larger indefinite delivery...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $11,605.50 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, and the contract carries no set-aside designation. The delivery order is scheduled for completion by September 24, 2025, and represents a single purchase under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order for XOLAIR 150 MG/ML syringes valued at $3,094.80. The contract, which was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, carries firm fixed-price terms and does not utilize a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 10, 2025, is scheduled for ultimate completion by October 1, 2025, with performance taking place at the awardee's Park Ridge facility. The contract was awarded without a set-aside designation,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency's Medical Supply Chain for the supply of Xolair 150 mg/ml syringes. The award, issued on August 29, 2025, with an ultimate completion date of September 22, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger single-award...
- The Defense Logistics Agency awarded a $1,547.40 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency (DLA) on September 4, 2025. The delivery order is for Xolair 150 mg/ml syringes, with an ultimate completion date of September 25, 2025. This award carries no set-aside designation, allowing the vendor to compete on equal footing in the federal procurement marketplace. The place of...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, valued at $27,907.20 with a firm fixed-price structure, is scheduled for completion by September 5, 2025, and was awarded on August 14, 2025. This delivery order carries no set-aside designation and leverages DMS Pharmaceutical Group's existing Indefinite...
- SPE2DB24D9144Indefinite Delivery Contract
- SPE2DB24D9144-SPE2DB25FCNAADelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,094.80 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its Park Ridge location with an ultimate completion date of October 2, 2025. This delivery order was issued without a set-aside designation, leveraging the company's competitive capabilities in the federal pharmaceutical supply market. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at approximately $500 million and valid through November 2026, known as the SPE2DB program. Under this master contract vehicle, the DLA issues firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting military health facilities worldwide. Xolair, a biologic medication used in the treatment of moderate-to-severe asthma and other conditions, represents one of the specialized pharmaceutical products within the contractor's extensive portfolio of branded medications, generics, biologics, and medical consumables available to support Department of Defense healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 9/11/25 |